Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 13 Apr 2026
Some Australians forced to choose 'between food and medicine', new survey finds
11 April 2026 - Australians are taking expired medication, skipping doses or opting to delay or not fill a prescription ...
Posted by Michael Wonder on 11 Apr 2026
MHRA approves olezarsen (Tryngolza) for the treatment of familial chylomicronaemia syndrome
10 April 2026 - The MHRA has today approved olezarsen (Tryngolza) to help treat adults with familial chylomicronaemia syndrome. ...
Posted by Michael Wonder on 11 Apr 2026
Cheaper medicines for people with cerebral palsy
10 April 2026 - The Australian Government is continuing to deliver cheaper medicines with Australians living with cerebral palsy to ...
Posted by Michael Wonder on 11 Apr 2026
FDA approves updated Vabysmo label to extend treatment for macular oedema following retinal vein occlusion beyond six months
9 April 2026 - Genentech has received US FDA approval of Vabysmo (faricimab-svoa) for the treatment of macular oedema due to ...
Posted by Michael Wonder on 10 Apr 2026
Celltrion’s ADC candidate CT-P71 wins FDA fast track in urothelial cancer
9 April 2026 - Celltrion announced Thursday that the US FDA has granted fast track designation to its antibody-drug conjugate ...
Posted by Michael Wonder on 10 Apr 2026
Cemiplimab in cutaneous squamous cell carcinoma: no suitable data due to insufficient observation period
16 March 2026 - To rule out a recurrence, patients must be monitored for a sufficient period of time, even after ...
Posted by Michael Wonder on 10 Apr 2026
FDA accepts NDA for TLX101-Px (Pixclara)
10 April 2026 - Telix today announces that the US FDA has accepted the Company’s resubmitted new drug application for TLX101-Px, ...
Posted by Michael Wonder on 10 Apr 2026
Wegovy injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
9 April 2026 - – The EMA has approved an update to the product information for Wegovy injection that allows ...
Posted by Michael Wonder on 10 Apr 2026
Replimune receives complete response letter from the FDA for RP1 biologics license application for the treatment of advanced melanoma
10 April 2026 - Replimune Group today announced that the company received a complete response letter from the US FDA ...
Posted by Michael Wonder on 10 Apr 2026
Foundayo (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the US
9 April 2026 - Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day ...
Posted by Michael Wonder on 10 Apr 2026
Sanofi becomes market authorisation holder for Nuvaxovid in Canada, expanding COVID-19 vaccine choices for Canadians
9 April 2026 - Nuvaxovid, a non-mRNA COVID-19 vaccine, will be made available in Canada by Sanofi for the fall 2026-2027 ...
Posted by Michael Wonder on 10 Apr 2026
Sobi receives Health Canada approval for Empaveli (pegcetacoplan) for the treatment of C3G and primary IC-MPGN
9 April 2026 - Approval supported by Phase 3 52 week VALIANT study demonstrated reduced proteinuria, stabilsed kidney function and ...
Posted by Michael Wonder on 09 Apr 2026
PHARMAC to fund two new combination treatments, and widen access to another, for people with a type of blood cancer
9 April 2026 - From 1 May 2026, people living with chronic lymphocytic leukaemia will be able to access two ...
Posted by Michael Wonder on 08 Apr 2026
Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps
8 April 2026 - GSK today announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) as an add-on ...
Posted by Michael Wonder on 08 Apr 2026
Access Consortium sets 2026 priorities to accelerate work-sharing and improve patient access to innovative medicines
7 April 2026 - The MHRA-led Access Consortium 2026 action plan will deepen collaboration, streamline work sharing, and speed up access ...